Stay updated on Nivolumab with Chemoradiation in NPC Clinical Trial
Sign up to get notified when there's something new on the Nivolumab with Chemoradiation in NPC Clinical Trial page.

Latest updates to the Nivolumab with Chemoradiation in NPC Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedThe page has undergone significant changes in the clinical study objectives, with a shift in focus from 1-year survival rates to 5-year survival rates and the addition of new exploratory objectives related to immune response monitoring and T-cell profiling.SummaryDifference8%
- Check26 days agoNo Change Detected
- Check33 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1.0%
- Check40 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.1%
- Check55 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.1%
- Check62 days agoChange DetectedThe study has updated its intervention type to 'Completed' and revised the follow-up schedule to extend patient monitoring for up to 4 years post-treatment, while removing the previous 'Active, not recruiting' status and shortening the follow-up period.SummaryDifference7%
- Check91 days agoChange DetectedThe website has been updated from version v2.13.2 to v2.13.3.SummaryDifference0.1%
Stay in the know with updates to Nivolumab with Chemoradiation in NPC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab with Chemoradiation in NPC Clinical Trial page.